Stopped: Undefined.
The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Best corrected visual acuity at six months and one year
Macular thickness measured by OCT at six months and one year
Median deviation in visual fields at one year
Score on a patient satisfaction scale at six months and one year